Scarica l'app Stockscreener
54.29
3.59%
1.88
Dopo l'orario di chiusura:
54.57
0.28
+0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$52.41
Aprire:
$53.495
Volume 24 ore:
21.87M
Relative Volume:
1.33
Capitalizzazione di mercato:
$110.52B
Reddito:
$48.03B
Utile/perdita netta:
$6.05B
Rapporto P/E:
18.33
EPS:
2.9615
Flusso di cassa netto:
$15.30B
1 W Prestazione:
+5.07%
1M Prestazione:
+16.38%
6M Prestazione:
+9.13%
1 anno Prestazione:
-2.67%
Intervallo 1D:
$53.01
$54.80
Intervallo di 1 settimana:
$50.33
$54.80
Portata 52W:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.29 | 106.69B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,062.19 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.17 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.45 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.19 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.26 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Assessing Bristol Myers Squibb After 16% Rally and New Drug Approvals in 2025 - simplywall.st
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Why Bristol-Myers Squibb (BMY) Stock Is Up Today - Finviz
Bristol-Myers Squibb Pops As BofA Upgrades Its Outlook - Finimize
Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says - marketscreener.com
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock? - Finviz
Bristol-Myers Squibb stock rating upgraded to Buy at BofA on pipeline strength - Investing.com
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions - Markets Financial Content
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More - AOL.com
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | - GuruFocus
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Pitcairn Co. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Checkpoint Inhibitors Market Is Going to Boom |Bristol-Myers Squibb • Merck & Co. - openPR.com
Caldwell Trust Co Makes New $1.70 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More - AOL.com
Bristol-Myers Squibb Shares Gain Momentum from Regulatory Advances - AD HOC NEWS
Buoyed by BMS milestones, Orum moves to build in-house clinical muscle - koreabiomed.com
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Coppell Advisory Solutions LLC Makes New $1.90 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Birchview Capital LP Has $14.97 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by AQR Capital Management LLC - MarketBeat
BMY Stock Rises: Analyst Upgrade to Buy & Opdivo FDA Priority Review | Dec 12, 2025News and Statistics - IndexBox
Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review - Oncodaily
Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? - Yahoo Finance
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street's 2026 Focus - ts2.tech
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum? - Yahoo Finance
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News - GuruFocus
Peapack Gladstone Financial Corp Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications - BioSpace
How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates - Yahoo Finance
BNP Paribas Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application - pharmiweb.com
Bristol Myers Squibb (BMY) Seeks FDA Approval for Expanded Opdiv - GuruFocus
Bristol Myers wins FDA priority review for Opdivo in first-line Hodgkin lymphoma - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Featured in Sector Research Coverage - Kalkine Media
Nathan Pennell: Proud of Bristol Myers Squibb Team Presenting at ASH25 - Oncodaily
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma - Yahoo Finance
Bristol-Myers Squibb’s Strategic Moves: A Dual Focus on Shareholder Returns and Oncology Expansion - Ad-hoc-news.de
Bristol Myers (BMY) Declares Increased Quarterly Dividend for 20 - GuruFocus
Bristol Myers Squibb raises quarterly dividend by 1.6% - Investing.com Nigeria
Bristol-Myers Squibb Raises Quarterly Dividend by 1.6% to $0.63 a Share, Payable on Feb. 2, 2026 to Shareholders of Record on Jan. 2, 2026 - marketscreener.com
Bristol Myers Squibb Announces Dividend Increase - marketscreener.com
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) t - GuruFocus
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating - marketscreener.com
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):